Treatment Status of Tyrosine Kinase Inhibitors in Chinese Patients with Chronic Myeloid Leukemia in 2020
H F Wang,Y L Zhang,X L Liu,H L Zhu,R Liang,B C Liu,L Zhou,L Meng,W M Li,Q Jiang
DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2021.07.002
2021-01-01
Abstract:Objective:To investigate the current status of treatment choice and responses in patients with chronic myeloid leukemia (CML) in China.Methods:From the end of April to mid-May in 2020, a cross-sectional survey, by filling out a survey questionnaire, was conducted to explore the first-line choice of tyrosine kinase inhibitors (TKI) , current medications, drug switch and major molecular responses (MMR) as well as the variables associated with them in patients in China.Results:Data of 2933 respondents with CML from 31 provinces, municipalities, and autonomous regions across the country were included in this study. 1683 respondents (57.4%) were males. Median age was 38 (16-87) years old. 2481 respondents (84.6%) received imatinib as first-line TKI; 1803 (61.5%) , the original new drug (branded drug) . When completing the questionnaire, 1765 respondents (60.2%) were receiving imatinib; 1791 (61.1%) , branded drug. 1185 respondents (40.4%) had experienced TKI switch. With a median follow-up of 45 (3-227) months, 1417 of 1944 (72.9%) respondents with newly diagnosed CML in the chronic phase achieved MMR. Multivariate analysis showed that the respondents with urban household registration ( OR=0.6, 95% CI 0.5-0.8, P<0.001) , ≥ bachelor degree ( OR=0.5, 95% CI 0.4-0.7, P<0.001) , and in the advanced phase at diagnosis ( OR=0.5, 95% CI 0.3-0.8, P=0.001) less preferred Chinese generic TKI, while the respondents from the central region in China more preferred Chinese generic TKI more than those from the eastern region ( OR=1.7, 95% CI 1.4-2.0, P<0.001) . Moreover, the respondents in the advanced phase at diagnosis more preferred second-generation TKI ( OR=5.4, 95% CI 3.6-8.2, P<0.001) ; those ≥60 years old, less preferred second-generation TKI ( OR=0.4, 95% CI 0.2-0.7, P=0.002) . Being in the advanced phase at diagnosis ( OR=2.2, 95% CI 1.6-3.2, P<0.001) , first-line choice of imatinib ( OR=2.0, 95% CI 1.6-2.6, P<0.001) or Chinese generic drugs ( OR=1.3, 95% CI 1.1-1.6, P=0.002) , longer interval from diagnose of CML to starting TKI treatment ( OR=1.2, 95% CI 1.1-1.2, P<0.001) and longer duration of TKI therapy ( OR=1.1, 95% CI 1.0-1.1, P<0.001) were significantly associated with TKI switch; urban household registration ( OR=0.7, 95% CI 0.6-0.8, P<0.001) , ≥MMR ( OR=0.6, 95% CI 0.5-0.8, P<0.001) and unknown response ( OR=0.7, 95% CI 0.6-0.9, P=0.003) , no TKI switch. Female sex ( OR=1.4, 95% CI 1.1-1.7, P=0.003) , urban household registration ( OR=1.6, 95% CI 1.3-2.0, P<0.001) , front-line imatinib therapy ( OR=1.4, 95% CI 1.1-1.9, P=0.016) and longer duration of TKI treatment ( OR=1.2, 95% CI 1.2-1.3, P<0.001) were significantly associated with achieving a MMR or better response; age ≥ 60 years old ( OR=0.7, 95% CI 0.4-1.0, P=0.047) and TKI switch ( OR=0.6, 95% CI 0.5-0.7, P<0.001) , achieving no MMR. Conclusions:By 2020, the majority of Chinese CML patients received imatinib as the fist-line TKI therapy and continue to take it. More than half of TKIs were branded drugs. Socio-demographic characteristics and clinical variables affect their TKI choice, drug switch, and treatment response.